文献速递淋巴瘤白血病

TRAIL介导并维持LGL白血病中NF-κB的组成性激活

TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia.
PubMed 文献 · Blood · 2018-04-26

本研究探讨TRAIL及其受体DcR2在LGL白血病NF-κB组成性激活中的作用。发现LGL白血病细胞TRAIL mRNA和蛋白表达上调,患者血清可溶性TRAIL升高,DcR2为主要TRAIL受体;TRAIL-DcR2信号激活NF-κB,阻断该信号则降低NF-κB活化;蛋白酶体抑制剂硼替佐米和伊沙佐米可抑制NF-κB并抑制增殖、促进凋亡。

要点

  • LGL白血病细胞TRAIL mRNA和蛋白表达上调,患者血清可溶性TRAIL升高。
  • DcR2是LGL白血病细胞主要的TRAIL受体,TRAIL-DcR2信号激活NF-κB。
  • 硼替佐米和伊沙佐米可降低LGL白血病细胞系和原代患者细胞增殖并增加凋亡。

核心结论

  • TRAIL与DcR2相互作用介导并维持LGL白血病中NF-κB的组成性激活,阻断TRAIL-DcR2信号可降低NF-κB活化。
  • 蛋白酶体抑制剂硼替佐米和伊沙佐米通过抑制NF-κB,降低LGL白血病细胞系和原代患者细胞的增殖并增加凋亡,提示潜在治疗应用。

研究设计与样本

  • 本研究为实验室研究,纳入LGL白血病患者样本和LGL白血病细胞系,检验TRAIL-DcR2信号对NF-κB激活的作用及蛋白酶体抑制剂的效应。

主要发现

  • LGL白血病细胞中TRAIL信使RNA和蛋白表达上调,LGL白血病患者血清中可溶性TRAIL蛋白水平升高。
  • DcR2是LGL白血病细胞中主要的TRAIL受体。
  • TRAIL诱导的DcR2激活导致白血病LGL中NF-κB活化增加;反之,阻断TRAIL-DcR2信号导致NF-κB活化降低。
  • 硼替佐米和伊沙佐米在LGL白血病细胞系和原代患者细胞中降低增殖并增加凋亡。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Large granular lymphocyte (LGL) leukemia results from clonal expansion of CD3+ cytotoxic T lymphocytes or CD3- natural killer (NK) cells. Chronic antigen stimulation is postulated to promote long-term survival of LGL leukemia cells through constitutive activation of multiple survival pathways, resulting in global dysregulation of apoptosis and resistance to activation-induced cell death. We reported previously that nuclear factor κB (NF-κB) is a central regulator of the survival network for leukemic LGL. However, the mechanisms that trigger constitutive activation of NF-κB in LGL leukemia remain undefined. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is known to induce apoptosis in tumor cells but can also activate NF-κB through interaction with TRAIL receptors 1, 2, and 4 (also known as DR4, DR5, and DcR2, respectively). The role of TRAIL has not been studied in LGL leukemia. In this study, we hypothesized that TRAIL interaction with DcR2 contributes to NF-κB activation in LGL leukemia. We observed upregulated TRAIL messenger RNA and protein expression in LGL leukemia cells with elevated levels of soluble TRAIL protein in LGL leukemia patient sera. We also found that DcR2 is the predominant TRAIL receptor in LGL leukemia cells. We demonstrated that TRAIL-induced activation of DcR2 led to increased NF-κB activation in leukemic LGL. Conversely, interruption of TRAIL-DcR2 signaling led to decreased NF-κB activation. Finally, a potential therapeutic application of proteasome inhibitors (bortezomib and ixazomib), which are known to inhibit NF-κB, was identified through their ability to decrease proliferation and increase apoptosis in LGL leukemia cell lines and primary patient cells.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Yang J, LeBlanc FR, Dighe SA, et al. TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia. Blood. 2018. PMID: 29699990. doi:10.1182/blood-2017-09-808816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。